Auxilium Pharmaceuticals, Inc. Announces Expansion of Its Exclusive License for XIAFLEX® (CCH) to Include the Potential

 Auxilium Pharmaceuticals, Inc. Announces Expansion of Its Exclusive License
   for XIAFLEX® (CCH) to Include the Potential Treatment of Cellulite as an
                            Additional Indication

PR Newswire

MALVERN, Pa., Jan. 7, 2013

MALVERN, Pa., Jan. 7, 2013 /PRNewswire/ --Auxilium Pharmaceuticals, Inc.
(NASDAQ: AUXL) ("Auxilium"), a specialty biopharmaceutical company, today
announced that it has exercised its exclusive option under the Second Amended
and Restated Development and License Agreement ("CCH License Agreement"),
dated as of August 31, 2011, with BioSpecifics Technologies Corp., Inc.
("BioSpecifics") to expand the field of its license for collagenase
clostridium histolyticum ("CCH") to include the potential treatment of adult
patients with edematous fibrosclerotic panniculopathy ("EFP"), commonly known
as cellulite. The Company exercised its option to include cellulite as an
additional indication by making a one-time license fee payment of $500,000 to
BioSpecifics. As a result of this exercise, the Company's exclusive,
world-wide license has now been expanded, subject to the terms of the CCH
License Agreement, to include all research, development, use,
commercialization, marketing, sales and distribution rights for CCH for the
potential treatment of cellulite.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

"We are encouraged by the initial safety profile and potential efficacy of CCH
in our recently completed phase Ib cellulite trial," said Adrian Adams, Chief
Executive Officer and President of Auxilium. "We believe cellulite represents
a significantly undertreated condition and that innovative approaches such as
CCH may, if approved, one day be a viable solution for treatment."

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum)
for the treatment of adult DC patients with a palpable cord in the U.S. GSK
co-promotes Testim with Auxilium in the U.S. Ferring International Center S.A.
markets Testim in certain countries of the EU and Paladin Labs Inc. markets
Testim in Canada. Pfizer has marketing rights for XIAPEX® (the EU tradename
for collagenase clostridium histolyticum) in 46 countries in Eurasia through
April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial
rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development
and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The
sBLA for XIAFLEX for the treatment of PD was submitted to the FDA on November
6, 2012 and has been accepted for Standard review with a PDUFA date of
September 6, 2013. Additionally, collagenase clostridium histolyticum (CCH) is
in phase IIa of development for the treatment of Frozen Shoulder syndrome
(adhesive capsulitis) and phase Ib of development for the treatment of
cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights
to pursue additional indications for CCH. For additional information, visit
http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements
regarding the potential for CCH to treat edematous fibrosclerotic
panniculopathy, commonly known as cellulite; the number of people with
cellulite and the market opportunity represented by that number; the clinical
development, safety profile and potential regulatory approval of CCH for the
treatment of cellulite; and products in development for Peyronie's disease,
Frozen Shoulder syndrome and cellulite; and all other statements containing
projections, statements of future performance or expectations, our beliefs or
statements of plans or objectives for future operations (including statements
of assumption underlying or relating to any of the foregoing). Forward-looking
statements can generally be identified by words such as "believe," "appears,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and other words and terms of similar meaning in
connection with any discussion of projections, future performance or
expectations, beliefs, plans or objectives for future operations (including
statements of assumption underlying or relating to any of the foregoing).
Actual results may differ materially from those reflected in these
forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions affecting
the biotechnology and pharmaceutical industries and those discussed in
Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the
year ended December 31, 2011 and Form 10-Q for the quarter ended September 30,
2012, which are on file with the Securities and Exchange Commission (the
"SEC") and may be accessed electronically by means of the SEC's home page on
the Internet at http://www.sec.gov or by means of Auxilium's home page on the
Internet at http://www.Auxilium.com under the heading "For Investors -- SEC
Filings." There may be additional risks that Auxilium does not presently know
or that Auxilium currently believes are immaterial which could also cause
actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans
or forecasts of future events and views as of the date of this release.
Auxilium anticipates that subsequent events and developments will cause
Auxilium's assessments to change. However, while Auxilium may elect to update
these forward-looking statements at some point in the future, Auxilium
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Auxilium's assessments as
of any date subsequent to the date of this release.

Auxilium Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com



SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com/
 
Press spacebar to pause and continue. Press esc to stop.